PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS

SUMMARY American tegumentary leishmaniasis is an infectious disease caused by a protozoan of the genus Leishmania. Pentavalent antimonials are the first choice drugs for cutaneous leishmaniasis (CL), although doses are controversial. In a clinical trial for CL we investigated the occurrence of panc...

Full description

Bibliographic Details
Main Authors:	Marcelo Rosandiski LYRA, Sonia Regina Lambert PASSOS, Maria Inês Fernandes PIMENTEL, Sandro Javier BEDOYA-PACHECO, Cláudia Maria VALETE-ROSALINO, Erica Camargo Ferreira VASCONCELLOS, Liliane Fatima ANTONIO, Mauricio Naoto SAHEKI, Mariza Mattos SALGUEIRO, Ginelza Peres Lima SANTOS, Madelon Noato RIBEIRO, Fatima CONCEIÇÃO-SILVA, Maria Fatima MADEIRA, Jorge Luiz Nunes SILVA, Aline FAGUNDES, Armando Oliveria SCHUBACH
Format:	Article
Language:	English
Published:	Universidade de São Paulo
Series:	Revista do Instituto de Medicina Tropical de São Paulo
Subjects:	Cutaneous leishmaniasis Therapy Clinical trial Meglumine antimoniate Pancreatitis
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652016005000252&lng=en&tlng=en

Similar Items

Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
by: Maria Inês Fernandes Pimentel, et al.

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
by: Erica de Camargo Ferreira e Vasconcellos, et al.
Published: (2014-07-01)

Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
by: Maria Cristina de Oliveira Duque, et al.

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
by: Cláudia Maria Valete-Rosalino, et al.
Published: (2014-09-01)

COMPARISON OF ORAL CHLOROQUINE WITH SYSTEMIC MEGLUMINE ANTIMONIATE IN TREATMENT OF CUTANEOUS LEISHMANIASIS
by: Muhammad Farooq, et al.
Published: (2021-02-01)

Novel methods for the encapsulation of meglumine antimoniate into liposomes
by: F. Frézard, et al.
Published: (2000-07-01)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
by: Deninson Alejandro Vargas, et al.
Published: (2019-06-01)

Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions
by: Jamyra Iglesias Cataldo, et al.

New onset of sinoatrial block in a young patient treated with systemic meglumine antimoniate
by: Najla Daadaa, et al.
Published: (2021-03-01)

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
by: Samanta Etel Treiger Borborema, et al.
Published: (2019-03-01)

In Vitro antileishmanial properties of neutron-irradiated meglumine antimoniate
by: Samanta Etel Treiger Borborema, et al.
Published: (2005-10-01)

Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
by: Margarita Arboleda, et al.
Published: (2019-05-01)

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
by: Lucia Regina Brahim, et al.

ELECTROCARDIOGRAPHIC CHANGES WITH STANDARD DOSE OF MEGLUMINE ANTIMONIATE THERAPY IN CUTANEOUS LEISHMANIASIS
by: Moizza Tahir, et al.
Published: (2021-08-01)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
by: Rosiana Estéfane da Silva, et al.
Published: (2016-08-01)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
by: Mohammad Omidian, et al.
Published: (2019-02-01)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
by: Dario Brock Ramalho, et al.
Published: (2018-06-01)

A Novel Strategy for Enhance Potentiation of Meglumine antimoniate against Leishmania major In Vitro
by: Farzaneh MIRZAEI, et al.
Published: (2019-12-01)

A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omiprazole in the treatment of cutaneous leishmaniasis
by: M.A. Nilforoushzadeh, et al.
Published: (2008-11-01)

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate
by: Olga Lucía Fernández, et al.
Published: (2021-09-01)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Madelon Novato Ribeiro, et al.
Published: (2014-07-01)

Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
by: D.A. Schettini, et al.
Published: (2005-12-01)

The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of Leishmania tropica
by: Hossein MAHMOUDVAND, et al.
Published: (2017-09-01)

Pentavalent Antimonials: New Perspectives for Old Drugs
by: Raul R. Ribeiro, et al.
Published: (2009-06-01)

Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity
by: Samanta Etel Treiger Borborema, et al.
Published: (2016-04-01)

In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L (L.) chagasi and L (Viannia) braziliensis
by: Eliane de Morais-Teixeira, et al.
Published: (2008-06-01)

[en] STUDIES ON THE BEHAVIOR OF MEGLUMINE ANTIMONIATE IN THE HUMAN BODY IN RHESUS MONKEYS
by: FLAVIA DE ALMEIDA VIEIRA
Published: (2008)

Distribution of liposome-encapsulated antimony in dogs
by: D.A. Schettini, et al.
Published: (2003-02-01)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
by: Weverson A. Ferreira, et al.
Published: (2014-04-01)

Antimonial treatment failure rate in patients with cutaneous leishmaniasis
by: Fariba Jaffary, et al.
Published: (2018-06-01)

Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis
by: Marta Maristany Bosch, et al.
Published: (2021-01-01)

Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Supplementary with Meglumine Antimoniate( Glucantime®) Against Cutaneous Leishmaniasis In BALB/C Mice
by: M Mohebali, et al.
Published: (2010-09-01)

Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Sup-plementary with Meglumine Antimoniate( Glucantime®) Against Cutaneous Leishmaniasis In BALB/C Mice
by: F Zamani Sorkhroodi, et al.
Published: (2010-09-01)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019-11-01)

Meglumine Antimoniate and Miltefosine Combined With Allopurinol Sustain Pro-inflammatory Immune Environments During Canine Leishmaniosis Treatment
by: Marcos Ferreira Santos, et al.
Published: (2019-10-01)

The Efficacy of Intralesional Meglumine Antimoniate (Glucantime) versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions
by: Mohammad Ali Nilforoushzadeh, et al.
Published: (2011-12-01)

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
by: Rosiana Estéfane da Silva, et al.

Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate
by: Atkinson, S., et al.
Published: (2021)

Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask
by: Sayed Abolfazl Mostafavi, et al.
Published: (2013-06-01)

Fatores associados ao insucesso do tratamento da leishmaniose cutânea com antimoniato de meglumina Factors associated with treatmet failure of cutaneous leishmaniasis with meglumine antimoniate
by: Alex Miranda Rodrigues, et al.
Published: (2006-04-01)